March 1, 2010Catheterization and Cardiovascular Interventions
Outcomes of diabetics receiving bare‐metal stents versus drug‐eluting stents
Why the study?
Do drug-eluting stents reduce target vessel revascularization and mortality in diabetic patients undergoing PCI compared to bare metal stents?
Population
1,319 patients with diabetes mellitus undergoing percutaneous coronary intervention (PCI)
Comparison
Drug-eluting stent(s) (DES) vs Bare metal stent(s) (BMS)
Design
Cohort
Follow-up
mean 2.5 years (maximum 5 years)
Authors
Discussion
Loading...
Member takes
Implication
DES may lower TVR in diabetic PCI patients; hypothesis-generating for survival benefit and requires RCT confirmation.
Structured PICO
Do drug-eluting stents reduce target vessel revascularization and mortality in diabetic patients undergoing PCI compared to bare metal stents?
P
Population
1,319 patients with diabetes mellitus undergoing percutaneous coronary intervention (PCI)
I
Intervention
Drug-eluting stent(s) (DES)
C
Comparator
Bare metal stent(s) (BMS)
O
Outcome
In-hospital outcomes (MACE), long-term rates of target vessel revascularization (TVR), and long-term mortalityhard clinical
In diabetic patients undergoing PCI, the use of drug-eluting stents significantly reduces the risk of target vessel revascularization compared to bare metal stents, with a non-significant trend toward improved survival.
Cite This Study
Ramanath et al. (2010) studied this question.